In the search for better therapies for neurodegenerative diseases like Parkinson’s, researchers are increasingly looking beyond classical drugs to the delivery systems that make them work. A fascinating example comes from a recent study published in npj Parkinson’s Disease [1], where scientists explored the effects of delphinidin — a natural flavonoid with anti-inflammatory potential — in a mouse model of Parkinson’s disease. What makes this work especially interesting is that delphinidin was delivered complexed with sulfobutyl ether β-cyclodextrin (SBECD). The complex preparation has been performed by CycloLab Ltd. The use of SBECD has been justified by the limited water solubility of delphinidin.
In this Parkinson’s study, delphinidin was administered as a complex with SBECD, leveraging cyclodextrin’s ability to keep the compound soluble and biologically accessible during systemic treatment in mice. This approach not only facilitated consistent dosing over nine weeks but also suggests a broader role for cyclodextrin derivatives in robust delivery of neuroprotective agents.
It has been found that daily delphinidin treatment in this Parkinson’s model partially reduced neuroinflammation, helped preserve striatal dopaminergic terminals, and modestly improved motor function, but did not save the actual dopaminergic neurons in the substantia nigra.
[1] Grotemeyer, A., Alexander, S., Frieß, L. et al. Delphinidin modulates neuroinflammation and behavioral deficits in a Parkinson’s disease mouse model. npj Parkinsons Dis. 12, 32 (2026). https://doi.org/10.1038/s41531-025-01244-0